Monthly Archives: December 2019

3 Latin American companies to watch in 2020

3 Latin American companies to watch in 2020

Although 2018 was a banner year for the Latin American cannabis industry, the amount of interest in the burgeoning cannabis market has decreased in 2019. Going forward, this is a trend that we do not expect will continue and believe that 2020 will be a transformational year for the Latin American cannabis market. 

From Canopy Growth (WEED.TO) (CGC) to Aurora Cannabis (ACB.TO) (ACB), some of the most high-profile names in the cannabis industry have made several strategic acquisitions of Latin American cannabis operators and this is a market that we have been bullish on. One of the main reasons for our bullish view on this market is related to the economics associated with cannabis and we believe that this provides operators with a major competitive advantage when compared to cannabis producers based in Canada. 

If you were to compare the average cost per gram of cannabis that is produced in Colombia to Canada, you will notice a major difference. In Latin America, it cost approx. $0.10 to produce each gram. In Canada, it costs approx. $1.00 to $1.50 to produce each gram and we find this to be of significance. 

In 2020, we expect to see the cannabis industry continue to record strong growth as new markets open and demand for products increase. Over the long-term, we believe that the companies that are scale operations in Latin American markets benefit from an ideal climate for cannabis cultivation and are the best positioned for growth we want to highlight 3 businesses that have been focused on this opportunity. 

Aurora Cannabis: Slow to Execute but an Opportunity to Watch

When we think of the Latin American cannabis industry, Aurora Cannabis is one of the first names to come to mind. In 2018, the Canadian cannabis producer acquired ICC Labs which was a first mover in the Latin American cannabis market. ICC was initially focused on the cannabis market in Uruguay and this is an opportunity that we are excited about. Uruguay was the first country in South America to legalize both medical and recreational cannabis and ICC was able to benefit from the first move advantage that it had on this market.

During the last few months, Aurora Cannabis has been under considerable pressure and has traded lower with the rest of the industry. When it comes to the international cannabis opportunity, the company has been slow to execute and we believe that this has impacted investor sentiment as it relates to the operation. 

From Europe to South America, Aurora Cannabis is one of the best diversified companies and own strategic assets and licenses in more than 20 cannabis markets across the world. Although Canada has been the most significant revenue driver for the business, we believe that the market wants to see the company start generating substantial revenues on the international side of the operation and we will be closely monitoring how the team is able to execute on this opportunity on a going forward basis. 

When looking at the reports published by leading Canadian broker-dealers, there is a major capital concern when it comes to Aurora Cannabis. The company has spent hundreds of millions of dollars on constructing cultivation facilities in Canada and the market believes that it does not have enough capital on hand to complete its international expansion. Going forward, we are of the opinion that the market will be highly focused on how the management team is able to advance operations in South America and in the European Union (EU). We believe that 2020 is a make or break year for the Canadian cannabis producer and this is a story that will have our full attention as we head into the new year. 

Chemesis International: A Global Growth Story in the Making

During the last year, we have seen a significant increase in the number of Canadian cannabis companies that are focused on the Latin America cannabis opportunity. In the US, the focus on the Latin American cannabis market was not as significant and only a few companies announced plans to capitalize on this opportunity. 

One US cannabis company that has been highly focused on the Latin American cannabis market is Chemesis International Inc. (CSE:CSI) (OTC:CADMF) (FRA:CWAA) and this is an opportunity that we are excited about. From California to Puerto Rico, Chemesis has been executing on a US expansion strategy and has attractive growth prospects heading into 2020. 

In early December, Chemesis reported a significant development after its wholly owned subsidiary, La Finca Interacviva-Arachna Med reported to be on track to complete its Agronomic Evaluation Programs in the first calendar quarter of 2020. The completion of the program represents a major milestone and brings the operation one step closer to registering its own genetics as intellectual property. 

Although this development did not generate traction with the market, there is a lot to look forward to when it comes to the Latin American side of the Chemesis business. By leveraging its own genetics, La Finca believes that it will be able to build a stable and consistent revenue stream as a global seed supplier. We are favorable on the amount of value that can be created through this vertical of the business and believe that the market under appreciates this aspect of the story. 

Going forward, Chemesis is focused on expanding its position in the Latin American market and La Finca continues to work to increase its land package through the Association for the Promotion of Cannabis Cultivation, a non-profit organization. The association works with local indigenous farming communities to provide education, technical advice, and a crop purchasing program. We are favorable on the growth prospects associated with a lager land package and will monitor how the management team is able to further expand its position.

Heading into 2020, we believe that one of the most significant growth initiatives for La Finca is related to how it continues to build its seed stock through cultivation. Starting in early 2020, the company expects to have considerably larger harvests and we expect the success of this initiative to be a major potential catalyst for growth. 

When cannabis companies expand operations, there tends to be an important transition period for the business where the cultivation team works to refine the growing process to optimize results from a quality and yield standpoint. Chemesis has been ahead of the curve with this and has secured a strategic relationship with the Universidad Nacional de Colombia to further refine seed genetics for each individual region. 

Through this relationship, the company is able to ensure high quality and consistent yields and we find this to be significant. Following the vaping health crisis, safety has become the largest concern for consumers and we are favorable on the process in place for La Finca. Going forward, we are bullish on the growth prospects associated with the Latin America side of the Chemesis operation. In the first calendar quarter of 2020, La Finca expects to harvest more than 5,000 kg of biomass and this is something that we are excited about. 

Chemesis believes that through its continued dedication for quality and compliance, La Finca will be a leader in cannabis cultivation, manufacturing and retail in Colombia. We believe that this aspect of the story is not fully appreciated by the street and are bullish on the growth prospects associated with the Latin American side of the business. If you look at the structure of the entire operation, we would not be surprised to see Chemesis spin-off La Finca as a standalone public company in 2020. The management team has been highly focused on creating value for shareholders and this would be a strategic way to do so. At current levels, Chemesis has an attractive risk-reward profile and this is an opportunity we are excited about heading into 2020. 

Blueberries Medical: What to Watch for in 2020

In early 2019, we started to notice an increase in interest in the Latin American cannabis market and several leading Canadian cannabis producers acquired assets that are levered to it. The valuations associated with these acquisitions were rich and the operations were acquired for massive premiums. Due to this, we became focused on early stage Latin American cannabis operators that were trading at huge discounts when compared to these acquisitions.

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) is an operator that caught our attention during this time and this is an opportunity that we have been highly focused on. A few weeks ago, the company announced a major change in the management team and appointed co-founder Camilo Villalba as CEO. We are favorable on the appointment and believe that it removed an important headwind from the operation. As CEO, Mr. Villalba will lead the company’s next phase of operational development, with initial exports expected during the first half of 2020. 

Timing could not have been better for this appointment and we are favorable on how the operation is positioned for growth. 2019 has been a banner year for the business and Blueberries is considered to be a leading operator in Colombia. Going forward, the company is well positioned for growth and has the necessary infrastructure in place to cultivate previous approved cannabis strains. Blueberries Medical is well positioned to ramp up production and meet local and international demand through its company owned facilities and also through agreements with contract growers.

When looking at Blueberries Medical, we see an operation that has substantial potential catalysts for growth and this is an opportunity that we are excited about. Last month, Blueberries reported a major milestone and harvested its first commercial crops at its 3.2-hectare Guatavita facility. The crops consist of five registered non-psychoactive cannabidiol (CBD) strains and we are bullish on the amount of value that can be created through the sale of the crops. 

We have been excited about the Guatavita opportunity due to the size of the existing facility as well as the potential it has to expand. Currently, the Guatavita facility has 150,000 square feet of open-air greenhouse with dedicated propagation and production facilities to allow the company to leverage local contract growers. When looking at the potential value drivers for the business in 2020, we are most excited about how the management team continues to advance its custom-built EU-GMP compliant extraction line (expected to be completed in January). In the first quarter of 2020, Blueberries expects start selling cannabis oil products and we are bullish on this aspect of the story.  

At current levels, Blueberries Medical is trading at a considerable discount to its peers and we find this to be of significance. The company has been working tirelessly on its Colombian expansion and we are impressed with how the story has advanced in such a short period of time. Under the leadership of Camilo Villalba as CEO, we believe that Blueberries Medical is well positioned for growth and is an opportunity to have on your radar.  

Pursuant to an agreement between StoneBridge Partners LLC and Chemesis International we have been hired for a period of 365 days beginning July 15, 2018 and ending July 15, 2019 to publicly disseminate information about (CSI) including on the Website and other media including Facebook and Twitter. We are being paid $5,000 per month for a period of 3 months. We own zero shares of (CSI), which we purchased in the open market. We plan to sell the “ZERO” shares of (CSI) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (CSI) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. This contract has been renewed for a period of 180 days beginning on August 2, 2019 and ending on February 2, 2020.

Share

Share - Facebook


Share - Twitter

Published at Mon, 30 Dec 2019 12:33:13 +0000

Georgia Medical Cannabis Board Holds First Meeting

Georgia Medical Cannabis Board Holds First Meeting

Editor’s Note: This article was updated on December 20, 2019.

It’s no secret that cannabis isn’t a cure-all. While regular consumption for recreational purposes at the ever-increasing potencies available on the legal market today still appears to have a fairly low level of health risk for the average person, potential cardiovascular impact remains an important consideration for those managing heart disease.

Due to the legal status of cannabis in the United States, studies on cannabis-related cardiovascular events have been primarily observational and self-reported, often pulling from small population samples without differentiation of consumption method. Aside from an incident with a 90mg THC lollipop, almost all studied risks of cannabis on cardiovascular function are based on users of inhaled combustible cannabis – and there’s plenty of data to suggest smoking of any kind may be of particular concern for those with pre-existing cardiovascular disease (CVD). Obviously, more complete clinical data is still needed, but there are a few red flags to consider already in regard to cannabis and heart health.

According to an article published by Harvard Medical School, patients with established heart disease who were also under stress have reported an increased likelihood of chest pain after smoking cannabis. THC, the primary psychoactive substance in adult-use market cannabis, has been shown to increase resting heart rate, dilate blood vessels, and make the heart pump harder – particularly within the first hour after smoking – raising concerns about an increased risk of heart attack immediately after consumption. These effects may be compounded by amplified stress levels within an individual.

Of course, as access continues to outpace transparent consumer education on responsible use, over-consumption of THC and the anxiety-producing effects that intolerance to high potencies can bring may be exasperating the experience of increased stress as well. So, while THC or other cannabinoids may correlate with cardiovascular changes, many of these symptoms may be more directly associated with raised anxiety levels after consuming or even other unknown factors.

© credit | Missouri State Medical Association

Possible confounders on indirect effects of cannabis on cardiovascular system.

According to numerous reports of increased emergency room visits from panicked consumers following legalization – absent of an immediate and major cardiac event – cardiovascular stress from induced anxiety generally subsides quickly and may be mitigated through cannabis avoidance or carefully measured dosing. Someone with a pre-existing heart condition who finds needed pain relief from cannabis may still be able to consume without significant risk but should be in communication with a cannabis-educated clinician or trained consultant who can provide observation and guidance. However, acute symptoms in consumers with pre-existing cardiac concerns may not be the only cardiological consideration with cannabis.

Regular Cannabis Use Linked to Structural Changes in the Heart

In a report released this week in the Journal of the American College of Cardiology (JACC) on Cardiovascular Imaging, researchers at Queen Mary University of London have found a possible link between regular cannabis use and its impact on structural and functional changes to the heart.

Funded by the British Heart Foundation, researchers analyzed MRI cardiac scans from a UK Biobank population study of 3,407 individuals without a history of CVD and identified an association between regular cannabis use, defined as daily or weekly use, and an enlarged left ventricle – the heart’s primary pumping chamber. Of the total population sample studied, 105 patients reported regular cannabis use in the past and only 47 who continued to consume cannabis regularly.

Despite the acknowledged imitations of the study, including a small sample size of self-reported use and a heavy Caucasian skew (96%), the study authors noted larger left ventricles and early signs of impaired heart function in the continued-use group. Past users who had not consumed cannabis in the five years prior to the interviews had similar heart size and function to those who had rarely or never imbibed, suggesting these concerns may be short-term side effects. No significant differences in overall left ventricular mass or the amount of blood ejected with each heartbeat was found in the study and no changes in the size and function of the other three heart chambers were identified.

Lead author Dr. Mohammed Khanji, Senior Clinical Lecturer at Queen Mary, provided commentary for the news release on this first-of-its-kind study: “Our findings are not conclusive but the research took place against a backdrop of decriminalization and legalization of recreational cannabis use in many countries. We urgently need systematic research to identify the long-term implications of regular consumption of cannabis on the heart and blood vessels. This would allow health professionals and policymakers to improve advice to patients and the wider public.”

Published at Fri, 20 Dec 2019 16:19:00 +0000

CP Logistics, LLC Reports That The Temporary Restraining Order Filing Against Sunniva Production Campus, LLC Was Denied

CP Logistics, LLC Reports That The Temporary Restraining Order Filing Against Sunniva Production Campus, LLC Was Denied

Sunniva Inc. (“Sunniva” or the “Company”) (CSE: SNN) (OTCQB: SNNVF), announces that the previously reported application for a Temporary Restraining Order (“TRO”), filed by its wholly owned subsidiary, CP Logistics, LLC (“CPL”), against the Sunniva Production Campus, LLC (“SPCL”) with respect to the Notice of Termination of Lease issued by SPCL, was denied in California Superior Court for the County of Riverside (the “Court”) on December 24, 2019. The Company is continuing to assert its rights under the Lease and has submitted a Demand for Arbitration and Notice of Claims with JAMS, the world’s largest private alternative dispute resolution provider, to initiate the arbitration process pursuant to the dispute resolution provisions of the Lease agreement for the property located at 69375 Ramon Road, Cathedral City, California.

(PRNewsfoto/Sunniva Inc.)

CPL, a wholly owned subsidiary of Sunniva, entered a build to suit lease agreement (the “Lease”) on October 20, 2017, with SPCL for the construction of the Sunniva California Campus in Cathedral City, California. SPCL is an entity related to Barker Pacific Group, Inc.

For more information about the Company please visit: www.sunniva.com.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Sunniva’s operations and growth opportunities and CP Logistics LLC’s submission of a Demand for Arbitration and Notice of Claims and the uncertainty regarding the future outcome of the Arbitration process, are “forward-looking information or statements”. Forward-looking information or statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Sunniva has made numerous assumptions including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking information or statements. Such risks and uncertainties include, among others, the risk factors included in the Sunniva’s continuous disclosure documents available on www.sedar.com. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking information or statements. Although Sunniva has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking information or statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. Sunniva assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Company Contacts:

Sunniva Inc.

Sunniva Investor Relations        

Dr. Anthony Holler

Rob Knowles

Chairman and Chief Executive Officer

VP Corporate Development

Phone: (866) 786-6482

Phone: (587) 430-0680  

Email: rknowles@Sunniva.com 

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/cp-logistics-llc-reports-that-the-temporary-restraining-order-filing-against-sunniva-production-campus-llc-was-denied-300979347.html

SOURCE Sunniva Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/26/c0773.html

Published at Thu, 26 Dec 2019 13:41:34 +0000

Canada House Wellness Group Reports Second Quarter Fiscal Year 2020 Results

Canada House Wellness Group Reports Second Quarter Fiscal Year 2020 Results

Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company“) is pleased to report its financial results for the three and six months ending October 31, 2019. All amounts are stated in thousands of Canadian dollars. Additional details can be found at www.sedar.com.

Canada House Wellness Group Inc. (CNW Group/Canada House Wellness Group Inc.)

Financial Highlights:

  • Cash position of $2,460 as at October 31, 2019 compared to $3,427 as at April 30, 2019 and $1,535 as at July 31, 2019. During the quarter, the Company secured $2.4 million of new financing and spent $484 on production-related capabilities.
  • Revenue for the three months ending October 31, 2019 was $1,291, an increase of $51 from $1,240 in the prior year and $2,581 for the six months ending October 31, 2019, an increase of $110 compared to $2,471 for the same period in the prior year.
  • Net Loss and Comprehensive Loss for the three months ending October 31, 2019 was $1,717 compared to Loss and Comprehensive loss of $3,007 for the same period in the prior year. For the six-month period ending October 31, 2019, net loss and comprehensive loss was $3,439compared to $5,035 for the same period in the prior year.
  • During the quarter ending October 31, 2019, general and administrative expenses decreased by $463 or 20% to $1,859 compared to $2,322for the quarter ending July 31, 2019.

“Receiving our amended sales license from Health Canada and the ability to sell our own production to medical cannabis patients and provincial retailers beginning October 1st, 2019 was a monumental milestone for Canada House.” says Chris Churchill Smith, CEO, Canada House. “We continue to focus on profitable growth from both Canada House Clinics and our Licensed Producer, Abba Medix Corp.  As revenue increases, we will continue to align our cost structure through disciplined cost management to grow stronger and drive profitability on a go-forward basis.”

About Canada House Wellness Group Inc.

Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from simple and complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.

Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally. Please visit www.canadahouse.ca.

Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canada House Wellness Group Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/27/c1437.html

Steven Pearce, Vice-President, Legal, Canada House Wellness Group Inc., 289-980-3584, spearce@canadahouse.caCopyright CNW Group 2019

Published at Fri, 27 Dec 2019 12:32:47 +0000

Missouri Issues Medical Cannabis Testing Lab Licenses

Missouri Issues Medical Cannabis Testing Lab Licenses

Editor’s Note: This article was updated on December 20, 2019.

It’s no secret that cannabis isn’t a cure-all. While regular consumption for recreational purposes at the ever-increasing potencies available on the legal market today still appears to have a fairly low level of health risk for the average person, potential cardiovascular impact remains an important consideration for those managing heart disease.

Due to the legal status of cannabis in the United States, studies on cannabis-related cardiovascular events have been primarily observational and self-reported, often pulling from small population samples without differentiation of consumption method. Aside from an incident with a 90mg THC lollipop, almost all studied risks of cannabis on cardiovascular function are based on users of inhaled combustible cannabis – and there’s plenty of data to suggest smoking of any kind may be of particular concern for those with pre-existing cardiovascular disease (CVD). Obviously, more complete clinical data is still needed, but there are a few red flags to consider already in regard to cannabis and heart health.

According to an article published by Harvard Medical School, patients with established heart disease who were also under stress have reported an increased likelihood of chest pain after smoking cannabis. THC, the primary psychoactive substance in adult-use market cannabis, has been shown to increase resting heart rate, dilate blood vessels, and make the heart pump harder – particularly within the first hour after smoking – raising concerns about an increased risk of heart attack immediately after consumption. These effects may be compounded by amplified stress levels within an individual.

Of course, as access continues to outpace transparent consumer education on responsible use, over-consumption of THC and the anxiety-producing effects that intolerance to high potencies can bring may be exasperating the experience of increased stress as well. So, while THC or other cannabinoids may correlate with cardiovascular changes, many of these symptoms may be more directly associated with raised anxiety levels after consuming or even other unknown factors.

© credit | Missouri State Medical Association

Possible confounders on indirect effects of cannabis on cardiovascular system.

According to numerous reports of increased emergency room visits from panicked consumers following legalization – absent of an immediate and major cardiac event – cardiovascular stress from induced anxiety generally subsides quickly and may be mitigated through cannabis avoidance or carefully measured dosing. Someone with a pre-existing heart condition who finds needed pain relief from cannabis may still be able to consume without significant risk but should be in communication with a cannabis-educated clinician or trained consultant who can provide observation and guidance. However, acute symptoms in consumers with pre-existing cardiac concerns may not be the only cardiological consideration with cannabis.

Regular Cannabis Use Linked to Structural Changes in the Heart

In a report released this week in the Journal of the American College of Cardiology (JACC) on Cardiovascular Imaging, researchers at Queen Mary University of London have found a possible link between regular cannabis use and its impact on structural and functional changes to the heart.

Funded by the British Heart Foundation, researchers analyzed MRI cardiac scans from a UK Biobank population study of 3,407 individuals without a history of CVD and identified an association between regular cannabis use, defined as daily or weekly use, and an enlarged left ventricle – the heart’s primary pumping chamber. Of the total population sample studied, 105 patients reported regular cannabis use in the past and only 47 who continued to consume cannabis regularly.

Despite the acknowledged imitations of the study, including a small sample size of self-reported use and a heavy Caucasian skew (96%), the study authors noted larger left ventricles and early signs of impaired heart function in the continued-use group. Past users who had not consumed cannabis in the five years prior to the interviews had similar heart size and function to those who had rarely or never imbibed, suggesting these concerns may be short-term side effects. No significant differences in overall left ventricular mass or the amount of blood ejected with each heartbeat was found in the study and no changes in the size and function of the other three heart chambers were identified.

Lead author Dr. Mohammed Khanji, Senior Clinical Lecturer at Queen Mary, provided commentary for the news release on this first-of-its-kind study: “Our findings are not conclusive but the research took place against a backdrop of decriminalization and legalization of recreational cannabis use in many countries. We urgently need systematic research to identify the long-term implications of regular consumption of cannabis on the heart and blood vessels. This would allow health professionals and policymakers to improve advice to patients and the wider public.”

Published at Fri, 20 Dec 2019 16:33:00 +0000

Metrc Sees Record Growth, Hires New Leadership Team in 2019

Metrc Sees Record Growth, Hires New Leadership Team in 2019

Editor’s Note: This article was updated on December 20, 2019.

It’s no secret that cannabis isn’t a cure-all. While regular consumption for recreational purposes at the ever-increasing potencies available on the legal market today still appears to have a fairly low level of health risk for the average person, potential cardiovascular impact remains an important consideration for those managing heart disease.

Due to the legal status of cannabis in the United States, studies on cannabis-related cardiovascular events have been primarily observational and self-reported, often pulling from small population samples without differentiation of consumption method. Aside from an incident with a 90mg THC lollipop, almost all studied risks of cannabis on cardiovascular function are based on users of inhaled combustible cannabis – and there’s plenty of data to suggest smoking of any kind may be of particular concern for those with pre-existing cardiovascular disease (CVD). Obviously, more complete clinical data is still needed, but there are a few red flags to consider already in regard to cannabis and heart health.

According to an article published by Harvard Medical School, patients with established heart disease who were also under stress have reported an increased likelihood of chest pain after smoking cannabis. THC, the primary psychoactive substance in adult-use market cannabis, has been shown to increase resting heart rate, dilate blood vessels, and make the heart pump harder – particularly within the first hour after smoking – raising concerns about an increased risk of heart attack immediately after consumption. These effects may be compounded by amplified stress levels within an individual.

Of course, as access continues to outpace transparent consumer education on responsible use, over-consumption of THC and the anxiety-producing effects that intolerance to high potencies can bring may be exasperating the experience of increased stress as well. So, while THC or other cannabinoids may correlate with cardiovascular changes, many of these symptoms may be more directly associated with raised anxiety levels after consuming or even other unknown factors.

© credit | Missouri State Medical Association

Possible confounders on indirect effects of cannabis on cardiovascular system.

According to numerous reports of increased emergency room visits from panicked consumers following legalization – absent of an immediate and major cardiac event – cardiovascular stress from induced anxiety generally subsides quickly and may be mitigated through cannabis avoidance or carefully measured dosing. Someone with a pre-existing heart condition who finds needed pain relief from cannabis may still be able to consume without significant risk but should be in communication with a cannabis-educated clinician or trained consultant who can provide observation and guidance. However, acute symptoms in consumers with pre-existing cardiac concerns may not be the only cardiological consideration with cannabis.

Regular Cannabis Use Linked to Structural Changes in the Heart

In a report released this week in the Journal of the American College of Cardiology (JACC) on Cardiovascular Imaging, researchers at Queen Mary University of London have found a possible link between regular cannabis use and its impact on structural and functional changes to the heart.

Funded by the British Heart Foundation, researchers analyzed MRI cardiac scans from a UK Biobank population study of 3,407 individuals without a history of CVD and identified an association between regular cannabis use, defined as daily or weekly use, and an enlarged left ventricle – the heart’s primary pumping chamber. Of the total population sample studied, 105 patients reported regular cannabis use in the past and only 47 who continued to consume cannabis regularly.

Despite the acknowledged imitations of the study, including a small sample size of self-reported use and a heavy Caucasian skew (96%), the study authors noted larger left ventricles and early signs of impaired heart function in the continued-use group. Past users who had not consumed cannabis in the five years prior to the interviews had similar heart size and function to those who had rarely or never imbibed, suggesting these concerns may be short-term side effects. No significant differences in overall left ventricular mass or the amount of blood ejected with each heartbeat was found in the study and no changes in the size and function of the other three heart chambers were identified.

Lead author Dr. Mohammed Khanji, Senior Clinical Lecturer at Queen Mary, provided commentary for the news release on this first-of-its-kind study: “Our findings are not conclusive but the research took place against a backdrop of decriminalization and legalization of recreational cannabis use in many countries. We urgently need systematic research to identify the long-term implications of regular consumption of cannabis on the heart and blood vessels. This would allow health professionals and policymakers to improve advice to patients and the wider public.”

Published at Fri, 20 Dec 2019 18:50:00 +0000

How Cannabis Entrepreneurs Can Explain What They Do For A Living — Without Freaking People Out

How Cannabis Entrepreneurs Can Explain What They Do For A Living — Without Freaking People Out

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Tue, 17 Dec 2019 21:30:00 +0000

Helpful Hints For Working With Family Members

Helpful Hints For Working With Family Members

eCann Media is proud to showcase our portfolio of investments and subsidiaries. We have completed numerous investments across multiple verticals and sectors in the cannabis industry. Requesting an invitation will enable the eCann team to consider your eligibility for investment as well help us to identify the opportunities that best fit your needs and investment objectives.

Published at Thu, 19 Dec 2019 21:30:00 +0000

This Week in Cannabis Investing December 20th

This Week in Cannabis Investing December 20th

Last week was a big week in the world of cannabis investing. We promised you another big week this week – and we delivered.

Without further ado…

Monday, we began the week by shining the spotlight on something that some investors may have thought didn’t exist: Marijuana Stock Winners for 2019. These aren’t just companies that made gains at some point of the year (and then lost them).

These are companies that recorded large gains in share price during the year. And even with the severe sell-off in the latter half of the year, they are set to close the year in positive territory.

We’re not talking obscure micro-caps here. We identified six cannabis companies strongly followed by investors (three in the U.S., three in Canada) that are up in 2019: Curaleaf Holdings (CAN:CURA / US:CURLF), Trulieve Cannabis (CAN:TRUL / US:TCNNF), Planet 13 Holdings (CAN:PLTH / US:PLNHF), Village Farms International (US:VFF / CAN:VFF), MediPharm Labs (CAN:LABS / US:MEDIF), and The Valens Company (CAN:VLNS / US:VGWCF).

Readers wanting the precise numbers for those winners can find that here.

We followed that up with some important news. Hot on the heels of Major League Baseball dropping cannabis as a “banned substance”, some very influential voices from the NFL are saying to expect changes (soon) in their cannabis rules too.

Tuesday, there was (surprise! surprise!) more good news from Colorado’s cannabis industry. The state is on track to set a record for cannabis sales for the 5th straight year, ready to clear last year’s record by a comfortable margin.

Wednesday, we went from looking at the best U.S. state (for legal cannabis) back to the worst: California. And (surprise! surprise!) as bad as the cannabis laws and regulations are in California, the state is contemplating ways to make things even worse.

Thursday, we gave The Seed Investor audience plenty to digest. First, we published our interview with Terry Donnelly. He’s the CEO of Hill Street Beverage Company (CAN:BEER / US:HSEEF). He’s also Co-Founder of the Cannabis Beverage Producers Alliance in Canada. Donnelly took the time to provide us with an in-depth look at the picture for cannabis-infused beverages in Canada.

On the downside, volume and carry limits for these products will be a burden for both beverage producers and consumers. More positively, Donnelly revealed that these beverages are expected to be price-competitive with alcohol products.

In comparison, U.S. cannabis-infused beverages retail for much higher prices. This may explain (to date) why these products have developed such a limited market share in U.S. legal cannabis markets.

Then we had an important exposé for our audience. It’s common knowledge among the People that the U.S. federal government is completely out of touch with reality when it comes to cannabis legalization. Now we’re hearing the same thing from someone inside Congress – a Kentucky Republican, no less (no, it was not Mitch McConnell).

We zeroed in on this cannabis truth-telling, likening it to a real-life version of The Emperor’s New Clothes.

Friday, we closed out the week with important news from both sides of the U.S./Canada border. South of the Border, Curaleaf reported a major cash infusion – US$275 million in pure debt financing. That will fund a lot of growth.

North of the Border, consolidation has begun within the province of Ontario with respect to cannabis store licenses. The one-year holding period for original licensees has now expired.

Some of these stores already have agreements in place to transfer these licenses. Others will be sold to the highest bidder. For Canadian cannabis companies (and cannabis investors) opportunity knocks.

In the last week before Christmas, the news flow hasn’t even begun to slow down for the cannabis industry. Probably that will change quickly next week. But with the cannabis industry, you never know.

At the least, readers can look forward to our 2019 Cannabis Review.
 

Published at Fri, 20 Dec 2019 22:24:03 +0000